Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue (2009 - 2024)

Alnylam Pharmaceuticals' Non-Current Deffered Revenue history runs 16 years deep, the most recent figure standing at $1.0 million for Q3 2024.

• Quarterly Non-Current Deffered Revenue fell 99.48% year-over-year to $1.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.0 million (down 99.48% YoY) and the FY2023 annual result came in at $188.2 million, down 2.9% from the prior year.
• Non-Current Deffered Revenue was $1.0 million for Q3 2024 at Alnylam Pharmaceuticals, down from $2.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $306.1 million in Q1 2020 and bottomed at $1.0 million in Q3 2024.
• A 5-year average of $180.9 million and a median of $191.3 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue jumped 63942.68% — and 2024, when it slumped 99.48%.
• Alnylam Pharmaceuticals' Non-Current Deffered Revenue stood at $225.1 million in 2020, then sank by 32.31% to $152.4 million in 2021, then increased by 27.19% to $193.8 million in 2022, then retreated by 2.9% to $188.2 million in 2023, then sank by 99.46% to $1.0 million in 2024.
• Business Quant data shows ALNY's Non-Current Deffered Revenue at $1.0 million in Q3 2024, $2.4 million in Q2 2024, and $185.5 million in Q1 2024.